BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37498656)

  • 21. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.
    Mahal BA; Chen YW; Muralidhar V; Mahal AR; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Yu JB; Feng FY; Kim SP; Beard CJ; Martin NE; Trinh QD; Nguyen PL
    Ann Oncol; 2017 May; 28(5):1098-1104. PubMed ID: 28453693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
    Tonttila PP; Lantto J; Pääkkö E; Piippo U; Kauppila S; Lammentausta E; Ohtonen P; Vaarala MH
    Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer.
    Quinn TP; Sanda MG; Howard DH; Patil D; Filson CP
    Cancer; 2021 Aug; 127(16):2974-2979. PubMed ID: 34139027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Location of Prostate Cancers Determined by Multiparametric and MRI-Guided Biopsy in Patients With Elevated Prostate-Specific Antigen Level and at Least One Negative Transrectal Ultrasound-Guided Biopsy.
    Schouten MG; Hoeks CM; Bomers JG; Hulsbergen-van de Kaa CA; Witjes JA; Thompson LC; Rovers MM; Barentsz JO; Fütterer JJ
    AJR Am J Roentgenol; 2015 Jul; 205(1):57-63. PubMed ID: 26102380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening.
    Segal N; Ber Y; Benjaminov O; Tamir S; Yakimov M; Kedar I; Rosenbaum E; Sela S; Ozalvo R; Shavit-Grievink L; Keder D; Baniel J; Margel D
    Ann Oncol; 2020 Nov; 31(11):1545-1552. PubMed ID: 32958357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding PSA and its derivatives in prediction of tumor volume: Addressing health disparities in prostate cancer risk stratification.
    Chinea FM; Lyapichev K; Epstein JI; Kwon D; Smith PT; Pollack A; Cote RJ; Kryvenko ON
    Oncotarget; 2017 Mar; 8(13):20802-20812. PubMed ID: 28160549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results.
    Beckmann K; Crawley D; Nordström T; Aly M; Olsson H; Lantz A; Binti Abd Jalal N; Garmo H; Adolfsson J; Eklund M; Van Hemelrijck M
    JAMA Netw Open; 2019 Nov; 2(11):e1914689. PubMed ID: 31693126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement of serum isoform [-2]proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of prostate cancer in patients with a total prostate-specific antigen level of 2-10 ng/ml.
    Furuya K; Kawahara T; Narahara M; Tokita T; Fukui S; Imano M; Mitome T; Ito Y; Izumi K; Osaka K; Yokomizo Y; Hayashi N; Hasumi H; Nawata S; Kawano T; Yao M; Uemura H
    Scand J Urol; 2017 Aug; 51(4):251-257. PubMed ID: 28351193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association Between Race/Ethnicity and Disparities in Health Care Use Before First-Episode Psychosis Among Privately Insured Young Patients.
    Heun-Johnson H; Menchine M; Axeen S; Lung K; Claudius I; Wright T; Seabury SA
    JAMA Psychiatry; 2021 Mar; 78(3):311-319. PubMed ID: 33355626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.
    Jayadevan R; Felker ER; Kwan L; Barsa DE; Zhang H; Sisk AE; Delfin M; Marks LS
    JAMA Netw Open; 2019 Sep; 2(9):e1911019. PubMed ID: 31509206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of prebiopsy magnetic resonance imaging of the prostate on cancer detection and treatment patterns.
    Liu W; Patil D; Howard DH; Moore RH; Wang H; Sanda MG; Filson CP
    Urol Oncol; 2019 Mar; 37(3):181.e15-181.e21. PubMed ID: 30514604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Barocas DA; Grubb R; Black A; Penson DF; Fowke JH; Andriole G; Crawford ED
    Cancer; 2013 Jun; 119(12):2223-9. PubMed ID: 23559420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies.
    Rais-Bahrami S; Siddiqui MM; Vourganti S; Turkbey B; Rastinehad AR; Stamatakis L; Truong H; Walton-Diaz A; Hoang AN; Nix JW; Merino MJ; Wood BJ; Simon RM; Choyke PL; Pinto PA
    BJU Int; 2015 Mar; 115(3):381-8. PubMed ID: 24447678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ethnic differences in prostate-specific antigen levels in men without prostate cancer: a systematic review.
    Barlow M; Down L; Mounce LTA; Merriel SWD; Watson J; Martins T; Bailey SER
    Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):249-256. PubMed ID: 36456698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng./ml.
    Fowler JE; Sanders J; Bigler SA; Rigdon J; Kilambi NK; Land SA
    J Urol; 2000 May; 163(5):1467-70. PubMed ID: 10751859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mediators of Racial Disparity in the Use of Prostate Magnetic Resonance Imaging Among Patients With Prostate Cancer.
    Leapman MS; Dinan M; Pasha S; Long J; Washington SL; Ma X; Gross CP
    JAMA Oncol; 2022 May; 8(5):687-696. PubMed ID: 35238879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contemporary Trends in Magnetic Resonance Imaging at the Time of Prostate Biopsy: Results from a Large Private Insurance Database.
    Kim SP; Karnes RJ; Mwangi R; Van Houten H; Gross CP; Gershman B; Leapman MS; Shah ND
    Eur Urol Focus; 2021 Jan; 7(1):86-94. PubMed ID: 31047904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mining laboratory data to describe prostate specific antigen testing and prostate cancer in Johannesburg, South Africa.
    Maphayi MR; Cassim N; Bello B; George JA
    Pan Afr Med J; 2020; 35():61. PubMed ID: 32537065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined Biparametric Prostate Magnetic Resonance Imaging and Prostate-specific Antigen in the Detection of Prostate Cancer: A Validation Study in a Biopsy-naive Patient Population.
    Fascelli M; Rais-Bahrami S; Sankineni S; Brown AM; George AK; Ho R; Frye T; Kilchevsky A; Chelluri R; Abboud S; Siddiqui MM; Merino MJ; Wood BJ; Choyke PL; Pinto PA; Turkbey B
    Urology; 2016 Feb; 88():125-34. PubMed ID: 26680244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
    Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
    BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.